Viking Therapeutics Q2 2021 Earnings Report
Key Takeaways
Viking Therapeutics reported a net loss of $15.4 million, or $0.20 per share, for the second quarter ended June 30, 2021. The company's cash, cash equivalents, and short-term investments totaled $228.3 million as of June 30, 2021, providing sufficient capital to advance clinical programs into late-stage development.
Enrollment continues in Phase 2b VOYAGE study evaluating VK2809 for the treatment of NASH.
Phase 1 study evaluating VK0214 achieved primary and secondary objectives; Phase 1b proof-of-concept trial in X-ALD patients underway.
Quarter-end cash of $228 million provides sufficient capital to advance clinical programs into late stage development.
VK2809-treated patients had significant reductions in plasma lipids, and median relative reductions in liver fat of up to approximately 60%.
Viking Therapeutics
Viking Therapeutics
Forward Guidance
Viking management will participate virtually in several upcoming investor events.